Basic research | The combination of Tau imaging agents and transgenic models can allow for: |
 | a) Non-invasive longitudinal tracking of tau pathology |
b) Longitudinal assessment of behavior as a function of tau pathology | |
c) Determination of pharmacokinetic properties | |
d) Development of novel radiopharmaceuticals | |
e) Development of theoretical models regarding progression of tau pathology | |
Clinical applications | The use of Tau imaging agents in the clinical approach can allow for: |
 | a) Early diagnosis |
b) Differential diagnosis | |
c) Follow-up of cognitive decline as function of tau pathology progression | |
d) Monitoring of treatment effectiveness of novel anti-tau and associated therapies | |
e) Development of theoretical models regarding tau pathology progression | |
f) Estimation of sample size and endpoints in the context of clinical trials |